Last reviewed · How we verify
Intramuscular DMPA
At a glance
| Generic name | Intramuscular DMPA |
|---|---|
| Sponsor | Johns Hopkins Bloomberg School of Public Health |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease (PHASE4)
- Continuation of Subcutaneous and Intramuscular Depot Medroxyprogesterone Acetate in Post-abortion Patients (PHASE4)
- Injectable Contraception Cohort Study in Punjab, Pakistan
- Kuwa Free! - Live Free! (NA)
- Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa (PHASE4)
- Contraceptive Hormones, Immunity, and Microbiome Evaluation
- Quantification of Immune Cells in Women Using Contraception (CHIC II)
- Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intramuscular DMPA CI brief — competitive landscape report
- Intramuscular DMPA updates RSS · CI watch RSS
- Johns Hopkins Bloomberg School of Public Health portfolio CI